Skip to contentB
Bioadaptives, Inc.
B
BDPTBioadaptives, Inc. Q2 2021 · 10-Q
Revenue$6.07K$6.07K+73.2% vs Q2 2020 Net Income-$309.25K-$309.25KN/M vs Q2 2020 EPS, diluted—
Gross Profit$3,352+2,180.3% Operating Cash Flowderived-$29,713N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bioadaptives, Inc. · CIK 1575142 · Engraved from SEC EDGAR
Margins · derivedGross margin55.3%+51.1 pt vs Q2 2020
Net margin-5098.9%+7192.3 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 12, 2021 · 43 d after period end